Bibliography
- Frazer IH , LeggattGR, MattarolloSR: Prevention and treatment of papillomavirus-related cancers through immunization.Annu. Rev. Immunol. DOI: 10.1146/annurev-immunol-031210-101308 (2010) (Epub ahead of print).
- Kim JJ , GoldieSJ: Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.BMJ339 , B3884 (2009).
- Palefsky JM : Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. Presented at: EUROGIN 2010. Monte Carlo, Monaco, 17–20 February 2010.
- Marklund L , HammarstedtL: Impact of HPV in oropharyngeal cancer.J. Oncol. DOI: 10.1155/2011/509036 (2011) (Epub ahead of print).
- Peres J : HPV-positive oropharyngeal cancer: data may justify new approach.J. Natl Cancer Inst.102 , 1456–1459 (2010).
- Allen CT , LewisJS Jr, El-Mofty SK, Haughey BH, Nussenbaum B: Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope120 , 1756–1772 (2010).
- Goon PK , StanleyMA, EbmeyerJ et al.: HPV & head and neck cancer: a descriptive update.Head Neck Oncol.1 , 36 (2009).
- Brandsma JL , SteinbergBM, AbramsonAL, WinklerB: Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx.Cancer Res.46 , 2185–2188 (1986).
- Brandsma JL , AbramsonAL: Association of papillomavirus with cancers of the head and neck.Arch. Otolaryngol. Head Neck Surg.115 , 621–625 (1989).
- Marur S , D‘SouzaG, WestraWH, ForastiereAA: HPV-associated head and neck cancer: a virus-related cancer epidemic.Lancet Oncol.11 , 781–789 (2010).
- Ang KK , HarrisJ, WheelerR et al.: Human papillomavirus and survival of patients with oropharyngeal cancer.N. Engl. J. Med.363 , 24–35 (2010).
- Hong AM , DobbinsTA, LeeCS et al.: Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy.Br. J. Cancer103 , 1510–1517 (2010).
- Lau HY , BrarS, KlimowiczAC et al.: Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy.Head Neck33 , 251–256 (2011).
- Hafkamp HC , ManniJJ, HaesevoetsA et al.: Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas.Int. J. Cancer122 , 2656–2664 (2008).
- Trimble CL , FrazerIH: Development of therapeutic HPV vaccines.Lancet Oncol.10 , 975–980 (2009).
- Kenter GG , WeltersMJ, ValentijnAR et al.: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.N. Engl. J. Med.361 , 1838–1847 (2009).
- Welters MJ , KenterGG, de Vos van Steenwijk PJ et al.: Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl Acad. Sci. USA107 , 11895–11899 (2010).
- Kreimer AR , CliffordGM, BoyleP, FranceschiS: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.Cancer Epidemiol. Biomarkers Prev.14 , 467–475 (2005).
- Wansom D , LightE, WordenF et al.: Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer.Arch. Otolaryngol. Head Neck Surg136 , 1267–1273 (2010).
- Albers A , AbeK, HuntJ et al.: Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.Cancer Res.65 , 11146–11155 (2005).
- Hoffmann TK , ArsovC, SchirlauK et al.: T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx.Int. J. Cancer118 , 1984–1991 (2006).
- Einstein MH , SchillerJT, ViscidiRP et al.: Clinician‘s guide to human papillomavirus immunology: knowns and unknowns.Lancet Infect. Dis.9 , 347–356 (2009).
- Sheu BC , LinRH, LienHC, HoHN, HsuSM, HuangSC: Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer.J. Immunol.167 , 2972–2978 (2001).